The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2019 | I-O monotherapy for advanced NSCLC
Martin Reck, MD, PhD, from Lung Clinic Grosshansdorf, Grosshansdorf, Germany, discusses the use of immuno-oncology agent monotherapy for the treatment of stage IV non-small cell lung cancer (NSCLC), referencing the results for pembrolizumab in the KEYNOTE-024 and KEYNOTE-042 trials. Speaking from the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland, Prof. Reck discusses the challenges faced in this field.
